University of Rome Tor Vergata, Department of Dermatology , Via Montpellier 1, 00133 Rome , Italy +39 339 566 8320 ; +39 062 090 2742 ;
Expert Opin Pharmacother. 2014 Mar;15(4):461-70. doi: 10.1517/14656566.2014.875159. Epub 2014 Jan 7.
Psoriasis is a common immune-mediated disorder that in 70% of cases appears in mild or mild-to-moderate form. Psoriasis is usually treated with topical medications and/or phototherapy with variable efficacy in controlling the disease.
For the past three decades, research has been focused on systemic agents for the treatment of moderate-to-severe psoriasis, particularly with the introduction of biologic agents or 'small molecules'. In parallel, novel advances in topical antipsoriatic agents have been made, experiencing a 'new era', with the development of new formulations and the identification of new therapeutic targets. These agents, having a different spectrum of action from traditional agents, are actually being tested in pre-marketing clinical trials and they may potentially represent promising treatment options that could enlarge the therapeutic armamentarium for the treatment of psoriasis.
Future antipsoriatic topical agents show new modality of action in blocking the pathogenic process leading to psoriatic plaque formation.
银屑病是一种常见的免疫介导性疾病,70%的病例表现为轻度或轻度至中度。银屑病通常采用局部药物治疗和/或光疗,但控制疾病的效果各不相同。
在过去的三十年中,研究一直集中在治疗中重度银屑病的系统性药物上,特别是生物制剂或“小分子”药物的引入。与此同时,新型局部抗银屑病药物也取得了新的进展,经历了一个“新时代”,开发了新的制剂并确定了新的治疗靶点。这些药物与传统药物的作用机制不同,正在进行上市前的临床试验,它们可能是有前途的治疗选择,可以扩大治疗银屑病的武器库。
未来的局部抗银屑病药物在阻断导致银屑病斑块形成的致病过程方面显示出新的作用模式。